Weekly Respiratory Research Analysis
This week features advances across surveillance, diagnostics, and translational therapies for respiratory disease. High-priority work includes functional characterization of diverse SARS‑CoV‑2–related bat coronaviruses informing spillover risk, demonstration that ferroptosis inhibition preserves liver and lung graft viability during ex vivo perfusion, and a multicentre randomized trial showing AI‑assisted mandibular movement monitoring accelerates obstructive sleep apnoea diagnosis while maintai
Summary
This week features advances across surveillance, diagnostics, and translational therapies for respiratory disease. High-priority work includes functional characterization of diverse SARS‑CoV‑2–related bat coronaviruses informing spillover risk, demonstration that ferroptosis inhibition preserves liver and lung graft viability during ex vivo perfusion, and a multicentre randomized trial showing AI‑assisted mandibular movement monitoring accelerates obstructive sleep apnoea diagnosis while maintaining clinical outcomes. Together the studies push surveillance and bedside diagnostics forward while opening translational paths for organ preservation and nucleic-acid therapeutics in airway disease.
Selected Articles
1. Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia.
Researchers sampled horseshoe bats in Thailand and identified two co-circulating clades of SARS‑CoV‑2–related coronaviruses. One clade binds human ACE2 but demonstrates reduced fusogenicity, replication, pathogenicity, and transmissibility compared with SARS‑CoV‑2; phylogeography and recombination analyses reveal extensive recent movement and recombination among lineages. The multimodal work (cryo‑EM, pseudovirus, live virus, hamster models) provides functional risk data to guide surveillance and preemptive countermeasure development.
Impact: Integrates structural, in vitro, in vivo, and phylogeographic data to functionally de-risk (or rank) bat sarbecoviruses with human ACE2-binding potential, offering an evidence base for surveillance prioritization and pandemic preparedness.
Clinical Implications: Improves genomic surveillance target selection and informs development of broadly protective countermeasures (e.g., pan-sarbecovirus antibodies/vaccines) and risk communication for spillover mitigation.
Key Findings
- Two distinct SC2r‑CoV clades co‑circulate in a single bat population in Thailand.
- One clade binds human ACE2 yet shows reduced fusogenicity, replication, pathogenicity, and transmissibility compared with SARS‑CoV‑2.
- Extensive recent geographic movement and inter-lineage recombination shape these viruses' evolution.
2. Ferroptosis inhibition enhances liver and lung graft function.
This translational study identified early lipid peroxidation during human liver transplantation and demonstrated that a dual-action ferroptosis inhibitor (FXT‑001) protects porcine liver and lung grafts during ex situ perfusion and preserves viability of declined human lungs in split ex‑vivo perfusion. Next‑generation compounds (FXT‑002/003) improved pharmacokinetics and safety, positioning ferroptosis blockade as a druggable strategy to reduce ischemia–reperfusion injury in transplantation.
Impact: Provides mechanistic validation and multi-species evidence, including declined human lungs, that ferroptosis drives graft injury and is pharmacologically targetable—opening a near‑term translational path for organ preservation and donor pool expansion.
Clinical Implications: Supports integrating ferroptosis inhibitors into ex vivo lung and liver perfusion protocols to reduce ischemia–reperfusion injury and potentially increase utilization and early function of marginal grafts; warrants early-phase clinical trials in EVLP/organ perfusion platforms.
Key Findings
- Early transient lipid peroxidation was identified in human liver transplants and validated as a therapeutic target.
- FXT‑001 protected porcine liver and lung grafts during ex situ perfusion and preserved viability of declined human lungs in split ex vivo perfusion.
- Next‑generation inhibitors (FXT‑002/FXT‑003) were developed with improved pharmacokinetics and safety profiles.
3. Time to diagnosis and treatment of obstructive sleep apnoea using mandibular jaw movement monitoring versus polysomnography: an open-label, multicentre, randomised, controlled trial.
The SUNSAS multicentre RCT (n=849) randomized adults with suspected OSA to AI‑supported mandibular jaw movement (MJM) monitoring versus in‑lab polysomnography. MJM was noninferior to PSG for reducing daytime sleepiness at 3 months and significantly shortened time to diagnosis and treatment initiation, producing earlier symptomatic benefit—demonstrating a scalable, home‑based diagnostic pathway that preserves clinical effectiveness.
Impact: Provides level‑1 randomized evidence that an AI‑assisted, home-based diagnostic device can safely accelerate OSA care pathways and decongest sleep-lab capacity—important for wide adoption and health-system planning.
Clinical Implications: Health systems can consider deploying AI‑supported MJM monitoring to reduce wait times for diagnosis and treatment initiation, expand access where PSG capacity is limited, and potentially improve early patient-reported outcomes.
Key Findings
- AI‑supported MJM monitoring was noninferior to PSG for Epworth Sleepiness Scale improvement at 3 months.
- MJM significantly shortened time to diagnosis and time to treatment initiation versus PSG.
- Earlier improvement in daytime sleepiness was observed attributable to accelerated diagnostic and treatment pathways.